tirzepatide and berberine Together: Safety & Drug Interactions – PlexusDx Berberine + Tirzepatide: Safety, Interactions

If additional glycemic control is needed after at least 30 days on the 7 mg dose, escalation to 14 mg once daily may be considered

GLP-1 therapies reduced inflammatory markers and protected kidney function in animals and humans, including in the FLOW trial

The FDA label includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though human relevance remains uncertain

DDI that result in drug overdose are responsible for serious and sometimes fatal adverse events

These agents mimic the action of naturally occurring GLP-1, an incretin hormone produced by intestinal L-cells in response to food intake